KEIO RESEARCHERS INFORMATION SYSTEM

Message from the Faculty Member 【 Display / hide 】

Message from the Faculty Member 【 Display / hide 】

• 医療薬学や臨床薬物動態学の楽しさを知っていただければと思います。

Profile Summary 【 Display / hide 】

Profile Summary 【 Display / hide 】

• 物理薬剤学や生物薬剤学、生化学、薬理学といった基礎薬学から、ヒトにおける臨床試験、患者や医療従事者を対象とした調査、疫学的調査、 医薬品情報、ファーマコメトリクス、ＩＴ技術にいたるさまざまな薬学領域の研究手法を活用することにより、おもに市販後の医薬品に関して、臨床的な問題点を解明し、適正かつ有効に使用するための 情報をつくるための研究を行っています。 具体的には、以下のような領域の研究を展開しています。 (1) 薬物の代謝過程やそこでの薬物相互作用の解析とテーラーメード医療への応用 (2) 消化管吸収過程における薬物相互作用の定量的予測 (3) 副作用軽減を目指した投与設計のための in vivo薬物動態・動力学的研究 (4) ＩＴ技術やファーマコメトリクスの活用による薬物治療の最適化

Other Affiliation 【 Display / hide 】

Other Affiliation 【 Display / hide 】

• Keio University Hospital, Department of Pharmacy, Director

• Faculty of Pharmacy, Department of Clinical Pharmacy, Concurrently appointed professor

Career 【 Display / hide 】

Career 【 Display / hide 】

• 1994.04

  -

  1999.01

  Research Associate, Pharmacist, The University of Tokyo Hospital

• 1999.01

  -

  1999.10

  Ohtani Estate Co., Ltd.

• 1999.11

  -

  2005.03

  Kyushu University, Graduate School of Pharmaceutical Sciences, Associate Professor

• 2005.04

  -

  2009.03

  Associate Professor, Graduate School of Pharmaceutical Sciences, The University of Tokyo

• 2008.04

  -

  2009.03

  Adjunct Associate Professor, Graduate School of Interdisciplinary Information Studies The University of Tokyo

display all >>

Academic Background 【 Display / hide 】

Academic Background 【 Display / hide 】

• 1986.04

  -

  1990.03

  The University of Tokyo, Faculty of Pharmaceutical Science, 薬学科

  University, Graduated

• 1990.04

  -

  1992.03

  The University of Tokyo, Graduate School of Pharmaceutical Sciences

  Graduate School, Completed, Master's course

Academic Degrees 【 Display / hide 】

Academic Degrees 【 Display / hide 】

• 博士 (薬学) Ph.D. (Pharmacy), The University of Tokyo, Dissertation, 1999.05

Licenses and Qualifications 【 Display / hide 】

Licenses and Qualifications 【 Display / hide 】

• Pharmacist, 1990.05

• JSPHCS-Certified Pharmacist, 2003.01

• JSCPT-Certified Pharmacist, 2021.12

• Certified National Tour Guide-Interpreter (English), 2016.02

• 第一種放射線取扱主任者, (2010/10/28 試験合格), 2018.06

display all >>

Research Areas 【 Display / hide 】

Research Areas 【 Display / hide 】

• Life Science / Clinical pharmacy (Clinical Pharmaceutical Science)

• Life Science / Pharmacology (Applied Pharmacology)

Research Keywords 【 Display / hide 】

Research Keywords 【 Display / hide 】

• pharmacometrics

• personalized medication

• interindividual variation of pharmacokinetics

• drug interactions

Books 【 Display / hide 】

Books 【 Display / hide 】

• The Manga Guide to Pharmacokinetics

  OHTANI Hisakazu, Ohmusha, Co., Ltd., 2021.05,  Page： 181

  • CiNii Research

• 臨床検査データブック 2025-2026.

  黒川 清(監修), 春日 雅人, 北村 聖, 大西 宏明(編集), 大谷 壽一 ほか 執筆., 医学書院, 東京, 2025.01

• これだけは気をつけたい! 高齢者への薬剤処方 第２版

  今井 博久 編集, 大谷 壽一 ほか 執筆, 株式会社 医学書院, 2024.02

  Scope: 高齢者の薬物動態,  Contact page： 18-31

• 世界第一簡單藥物動力學 (「マンガでわかる薬物動態学」中国語(繁字)版)

  大谷　壽一, 世茂出版有限公司, 2022.10,  Page： 192

• 만화로 쉽게 배우는 약물동태학 (「マンガでわかる薬物動態学」韓国語版)

  大谷　壽一, 성안당, 2022.08,  Page： 192

display all >>

Papers 【 Display / hide 】

Papers 【 Display / hide 】

• Performance Improvement of a Natural Language Processing Tool for Extracting Patient Narratives Related to Medical States From Japanese Pharmaceutical Care Records by Increasing the Amount of Training Data: Natural Language Processing Analysis and Validation Study

  Ohno Y., Aomori T., Nishiyama T., Kato R., Fujiki R., Ishikawa H., Kiyomiya K., Isawa M., Mochizuki M., Aramaki E., Ohtani H.

  JMIR Medical Informatics 13   e68863 2025.12

  Research paper (scientific journal), Joint Work, Corresponding author, Accepted

  　View Summary

  Background: Patients’ oral expressions serve as valuable sources of clinical information to improve pharmacotherapy. Natural language processing (NLP) is a useful approach for analyzing unstructured text data, such as patient narratives. However, few studies have focused on using NLP for narratives in the Japanese language. Objective: We aimed to develop a high-performance NLP system for extracting clinical information from patient narratives by examining the performance progression with a gradual increase in the amount of training data. Methods: We used subjective texts from the pharmaceutical care records of Keio University Hospital from April 1, 2018, to March 31, 2019, comprising 12,004 records from 6559 cases. After preprocessing, we annotated diseases and symptoms within the texts. We then trained and evaluated a deep learning model (bidirectional encoder representations from transformers combined with a conditional random field [BERT-CRF]) through 10-fold cross-validation. The annotated data were divided into 10 subsets, and the amount of training data was progressively increased over 10 steps. We also analyzed the causes of errors. Finally, we applied the developed system to the analysis of case report texts to evaluate its usability for texts from other sources. Results: The F<inf>1</inf>-score of the system improved from 0.67 to 0.82 as the amount of training data increased from 1200 to 12,004 records. The F<inf>1</inf>-score reached 0.78 with 3600 records and was largely similar thereafter. As performance improved, errors from incorrect extractions decreased significantly, which resulted in an increase in precision. For case reports, the F<inf>1</inf>-score also increased from 0.34 to 0.41 as the training dataset expanded from 1200 to 12,004 records. Performance was lower for extracting symptoms from case report texts compared with pharmaceutical care records, suggesting that this system is more specialized for analyzing subjective data from pharmaceutical care records. Conclusions: We successfully developed a high-performance system specialized in analyzing subjective data from pharmaceutical care records by training a large dataset, with near-complete saturation of system performance with about 3600 training records. This system will be useful for monitoring symptoms, offering benefits for both clinical practice and research.

  • Access to Document (DOI)

• Proton Pump Inhibitors Attenuate the Effectiveness of Nivolumab Monotherapy in Patients with Advanced Gastric Cancer: A Retrospective Study.

  Yamaguchi M, Kawazoe H, Kasai Y, Hirata K, Ohtani H

  Journal of Gastrointestinal Cancer (Springer)  56 ( 1 ) 226 2025.11

  Research paper (scientific journal), Joint Work, Last author, Accepted

  • Access to Document (DOI)

• Inhibition kinetics of citrus jabara juice and its components on CYP2C9 activity

  Koinuma K., Morita T., Uekusa Y., Kikuchi H., Imaoka A., Akiyoshi T., Ohtani H.

  Journal of Pharmaceutical Sciences 114 ( 11 ) 103983 2025.11

  Research paper (scientific journal), Joint Work, Last author, Corresponding author, Accepted,  ISSN  00223549

  　View Summary

  Our previous studies demonstrated that the ethyl acetate extract of the juice of jabara (JEx), a Japanese citrus fruit, inhibited cytochrome P450 (CYP) 3A4 activity in a time-dependent manner, but does not inhibit CYP2C19 activity. Its components, 3,3′,4′,5,6,7,8-heptamethoxyflavone (HpMF) and 3,3′,4′,5,6,7-hexamethoxyflavone (HxMF), have been shown to be responsible for this CYP3A4 inhibition. This study aimed to investigate the nature of CYP2C9 inhibition by JEx, HpMF, and HxMF. The time-dependent inhibition kinetics of JEx against human recombinant CYP2C9 were investigated in vitro using warfarin as a substrate. The time-independent inhibition kinetics of JEx, HpMF, and HxMF against CYP2C9 were also determined. JEx did not cause time-dependent inhibition of CYP2C9, while JEx, HpMF, and HxMF inhibited CYP2C9 activity in a time-independent manner with IC<inf>50</inf> values of 2.65 % equivalent, 16.2 µM, and 57.8 µM, respectively. HpMF and HxMF were considered to be primarily responsible for CYP2C9 inhibition by JEx. The ingestion of 250 mL of jabara juice was estimated to reduce intestinal CYP2C9 activity to 3 % of the control value assuming of dilution with 210 mL of intestinal fluid, suggesting that jabara juice may cause food-drug interactions via intestinal CYP2C9 inhibition.

  • Access to Document (DOI)

• The effect of organic solvents on the in vitro transport activity of three OATP isoforms

  Saito R., Akiyoshi T., Tsujii K., Takahashi R., Kataoka H., Imaoka A., Ohtani H.

  Toxicology in Vitro 107   106059 2025.08

  Last author, Accepted,  ISSN  08872333

  　View Summary

  Purpose: In vitro studies of transporter activity often require the addition of organic solvents such as dimethyl sulfoxide (DMSO), methanol, and ethanol, to dissolve substrates and/or inhibitors. Although this may attenuate the transport activity, the influence of different types of organic solvents on transporter activity has not been elucidated. This study aimed to quantitatively assess the impact of organic solvents on the transport activity of organic anion transporting polypeptide (OATP) 1B1, 1A2, and 2B1. Methods: The concentration-dependent influence of DMSO, methanol, and ethanol on the uptake of [³H]estrone 3-sulfate mediated by OATP1A2, OATP2B1 or 2′,7′-dichlorofluorescein (DCF) mediated by OATP1B1 was assessed using HEK293 cells expressed the respective OATP protein and the concentration that reduced the uptake by 20 % (IC<inf>20</inf>) was calculated. Results and discussion: The uptake activities of OATPs were reduced by methanol and ethanol in a concentration-dependent manner, with IC<inf>20</inf> values of 2.4–3.4 % and 0.51–3.8 % respectively. In contrast, DMSO did not affect the OATP2B1-mediated uptake at the maximum concentration (10 %) of DMSO whereas it exhibited concentration-dependent inhibition for OATP1B1 and 1A2 with IC<inf>20</inf> values of approximately 3 % and 0.7 %, respectively. This study provides useful information regarding experimental conditions for evaluating OATPs activity in vitro.

  • Access to Document (DOI)

• Comparative analysis of the single-molecule transport kinetics of OATP1B1 genetic variants

  Tsujii K., Yajima K., Akiyoshi T., Sakamoto K., Suzuki Y., Oka T., Imaoka A., Yamamura H., Kurokawa J., Ohtani H.

  Journal of Pharmacological Sciences 158 ( 3 ) 166 - 171 2025.07

  Research paper (scientific journal), Joint Work, Last author, Corresponding author,  ISSN  13478613

  　View Summary

  Several genetic variants of OATP1B1, a hepatic uptake transporter, increase the blood concentrations of substrate drugs, e.g., ∗15 carriers exhibit higher blood substrate concentrations than ∗1b carriers. It remains unclear whether these differences are due to changes in expression or intrinsic activity (transport activity per OATP1B1 molecule). This study compared the intrinsic activity of four OATP1B1 variants, ∗1a, ∗1b, ∗5, and ∗15, using HEK293 cell lines that co-expressed large-conductance Ca²⁺-activated K⁺ (BK) channels and one of the OATP1B1 variants. To estimate the kinetic parameters K<inf>m</inf> and V<inf>max</inf>, 2′, 7′-dichlorofluorescein uptake was evaluated. The number of OATP molecules per cell (Q<inf>T</inf>) was calculated from BK channel-mediated whole-cell conductance and the OATP1B1/BK channel expression ratio (ρ) (determined by LC-MS/MS). V<inf>max,int</inf> (maximum intrinsic transport velocity) was obtained by dividing V<inf>max</inf> by Q<inf>T</inf>, and intrinsic clearance (CL<inf>int</inf>) was calculated as V<inf>max,int</inf>/K<inf>m</inf>. The K<inf>m</inf> values of ∗1a, ∗1b, ∗5, and ∗15 were 12.5, 9.19, 7.53, and 10.4 μM, and their V<inf>max,int</inf> values were 3.0, 7.0, 1.5, and 1.2 × 10⁻²¹ mol/OATP molecule/min, respectively. Accordingly, the CL<inf>int</inf> value for OATP1B1∗15 was 15 % lower than that for OATP1B1∗1b, suggesting that the increased blood substrate concentrations observed in OATP1B1∗15 carriers may be due to the decreased intrinsic activity of OATP1B1∗15.

  • Access to Document (DOI)

display all >>

Papers, etc., Registered in KOARA 【 Display / hide 】

Papers, etc., Registered in KOARA 【 Display / hide 】

• Analysis of the inter-individual variations of food-drug interactions via CYP2Cs and OATPs

  Ohtani, Hisakazu

  科学研究費補助金研究成果報告書 2020

• Quantitative analysis of the factors that confer inter-individual variation of the extent of beverage-drug interactions

  Otani, Hisakazu

  科学研究費補助金研究成果報告書 2017

• The effect of gastrointestinal damage on drug absorption

  Otani, Hisakazu

  科学研究費補助金研究成果報告書 2017

• Quantitative analysis of genetic factors affecting the extent of drug interactions via mechanism based inhibition of cytochrome P450

  Otani, Hisakazu

  科学研究費補助金研究成果報告書 2014

Reviews, Commentaries, etc. 【 Display / hide 】

Reviews, Commentaries, etc. 【 Display / hide 】

• カフェイン副作用説明の有無によるノセボ効果発現の主観的評価と遺伝的要因の影響

  奥田 りりか, 泉谷 優佳, 本間 遥香, 井澤 美苗, 清宮 啓介, 石川 春樹, 望月 眞弓, 青森 達, 大谷 壽一

  日本医薬品情報学会総会・学術大会講演要旨集 ((一社)日本医薬品情報学会)  27回   105 - 105 2025.06

• 自然言語処理技術を用いたバンコマイシン塩酸塩による有害事象の症例検出

  大野 由紀子, 青森 達, 清宮 啓介, 西山 智弘, 奥田 りりか, 疋田 夕真, 河添 仁, 望月 眞弓, 荒牧 英治, 大谷 壽一

  日本医薬品情報学会総会・学術大会講演要旨集 ((一社)日本医薬品情報学会)  27回   106 - 106 2025.06

• 胃がん患者において併用薬がニボルマブの有効性に与える影響　単施設後方視的観察研究

  山口 未来望, 河添 仁, 笠井 雄佑, 平田 賢郎, 大谷 壽一

  日本医薬品情報学会総会・学術大会講演要旨集 ((一社)日本医薬品情報学会)  27回   104 - 104 2025.06

• エンホルツマブベドチン投与時の有害事象軽減を目的としたデキサメタゾン予防投与の評価

  石井 紗英子, 末廣 直哉, 長島 彩乃, 櫻井 洋臣, 村松 博, 河添 仁, 大谷 壽一

  日本臨床腫瘍薬学会雑誌 ((一社)日本臨床腫瘍薬学会)  41   159 - 159 2025.05

• 生成AIの臨床薬学領域における利活用の現状　文献レビュー

  清宮 啓介, 青森 達, 河添 仁, 大谷 壽一

  医療薬学 ((一社)日本医療薬学会)  51 ( 4 ) 177 - 186 2025.04

  Article, review, commentary, editorial, etc. (scientific journal), Joint Work, Last author,  ISSN  1346-342X

  　View Summary

  生成AIには現在「ChatGPT-3.5」「ChatGPT-4」「ChatGPT-4o」「Gemini 1.0 Pro」「Claud instant」などがある。今回、各々の特徴について概説し、臨床薬学領域で生成AIを活用している研究について以下の項目別に列挙した。1)ChatGPT3.5のみを対象とした研究。2)ChatGPT-4のみを対象とした研究。3)異なる生成AI間での比較研究。

  • Access to Document (DOI)

display all >>

Presentations 【 Display / hide 】

Presentations 【 Display / hide 】

• Drug-beverage interaction

  Hisakazu Ohtani

  [International presentation]  29th Dubai International Pharmaceutical & Technologies Conference & Exhibition - DUPHAT (Dubai) , 

  2023.01

  , 

  Oral presentation (invited, special)

• Pharmacy education in Japan - Clinical rotation and preceptorship -

  OHTANI Hisakazu

  [International presentation]  Seminar National. Asosiasi Pendidikan Tinggi Farmasi Indonesia (APTFI) II (Banjarmasin, Indonesia) , 

  2017.11

  , 

  Oral presentation (invited, special), Association of Indonesian Pharmacy Higher Education (APTFI)

• 医療連携で薬剤師に求められる臨床薬物動態学の基本

  OHTANI Hisakazu

  [Domestic presentation]  日本薬学会関東支部 薬剤師向け研修講演会 (前橋) , 

  2017.10

  , 

  Public lecture, seminar, tutorial, course, or other speech, 日本薬学会関東支部

  yakuzaishi2017.pdf

• 受理される論文・されない論文

  OHTANI Hisakazu

  [Domestic presentation]  第１回 医療薬学教育セミナー (東京) , 

  2017.04

  , 

  Public lecture, seminar, tutorial, course, or other speech, 日本医療薬学会

• CYP3A4 genetic variants に対する各種アゾール系抗真菌薬の阻害特性の比較.

  川村 豪, 今岡 鮎子, 秋好 健志, 日比野 英幸, 荒木 拓也, 宮崎 光江, F.P Guengerich, 中村 克徳, 中村 智徳, 山本 康次郎, 大谷 壽一

  [Domestic presentation]  日本薬学会第 137 年会 (仙台) , 

  2017.03

  , 

  Poster presentation

display all >>

Research Projects of Competitive Funds, etc. 【 Display / hide 】

Research Projects of Competitive Funds, etc. 【 Display / hide 】

• CYP2Cs及びOATPsを介した薬物ー飲食物間相互作用とその個人差の定量的解明

  2018.04

  -

  2021.03

  日本学術振興会, Grant-in-Aid for Scientific Research, Research grant, Principal investigator

• Analysis of the inter-individual variations of food-drug interactions via CYP2Cs and OATPs

  2018.04

  -

  2021.03

  MEXT,JSPS, Grant-in-Aid for Scientific Research, Ohtani Hisakazu, Grant-in-Aid for Scientific Research (C), Principal investigator

  　View Summary

  The mechanism of food-drug interactions includes the inhibition of metabolic enzymes or drug transporters, which have genetic variations. The aim of this study is to clarify whether the genetic variations of metabolic enzymes and transporters lead to the altered inhibitory kinetics of respective inhibitors contained in a variety of fruit juices. We focused upon two metabolic enzymes (CYP2C9 and CYP2C19) and two transporters (OATP1A2 and OATP2B1). Detailed analysis revealed that the inhibitory kinetics of various inhibitors highly differ among genetic variants. Therefore, the genetic variants of metabolic enzymes and drug transporters are considered to be one of the important factors to confer inter-individual variation in the extent of food-drug interactions. We also succeeded in identifying a novel OATP inhibitor, narirutin, from grape fruit juice.

• 薬物−飲食物間相互作用の強度に個人差をもたらす遺伝的要因の解明

  2015.04

  -

  2018.03

  日本学術振興会, Grant-in-Aid for Scientific Research, Principal investigator

• Quantitative analysis of the factors that confer inter-individual variation of the extent of beverage-drug interactions

  2015.04

  -

  2018.03

  MEXT,JSPS, Grant-in-Aid for Scientific Research, Hisakazu OHTANI, AKIYOSHI Takeshi, IMAOKA Ayuko, Grant-in-Aid for Scientific Research (C), Principal investigator

  　View Summary

  The influences of genetic variation of CYP3A4 on the inhibitory kinetics of its inhibitors varied among the inhibitors and affected by the probe substrate used. The inhibitor manners (patterns) of metabolic inhibitors contained in fruit juice are different among CYP isoforms, i.e. CYP3A4, 2C9 and 2C19. The research should be focused upon the mode of inhibition that is clinically most relevant.
  Using newly developed cell lines stably expressing a transporter OATP1A2 or OATP2B1, some unidentified inhibitory ingredient(s) for these transporters are considered to be contained in some fractions of grapefruit juice.

• Quantitative analysis of genetic factors affecting the extent of drug interactions via mechanism based inhibition of cytochrome P450

  2012.04

  -

  2015.03

  Keio University, Grant-in-Aid for Scientific Research, Hisakazu Ohtani, YAMAMOTO Koujirou, AKIYOSHI Takeshi, YAMAZAKI Hiroshi, Grant-in-Aid for Scientific Research (C), Research grant, Principal investigator

  　View Summary

  There seems to be considerable inter-individual variations in the extent of drug interactions, especially via the inhibition of oxidative metabolic enzymes, P450s. This study aimed to investigate quantitatively the influence of genetic variation of P450s, such as CYP3A4 and CYP2D6, on the extent of drug interaction in the in vitro studies using genetic variants. As a result of enzymatic study with probe substrates and mechanism-based inhibitors (MBI), we concluded that the inhibitory potencies of MBI differ among genetic variants. These results suggest that the genetic variation of metabolic enzymes affect the extent of drug interactions caused by their inhibitors, as well as the pharmacokinetics of their substrate drugs.

display all >>

Awards 【 Display / hide 】

Awards 【 Display / hide 】

• 日本医療薬学会賞

  2023.11, 日本医療薬学会, 薬物相互作用の個人差に関する医療薬学的研究

  Type of Award： Award from Japanese society, conference, symposium, etc.

• 日本医療薬学会奨励賞

  2007.09, 日本医療薬学会, 薬物動態・動力学の活用によるテーラーメイド処方設計支援システムの基盤技術の確立

• 年会優秀発表賞

  "丹羽しおり, 秋好健志, 今岡鮎子, 大谷壽一.", 2014.03, 日本薬学会第134年会, In vitro データをもとにした、CYP2D6 variants における paroxetine の非線型体内動態の予測.

• 最優秀ポスター賞

  "三井梨恵子, 秋好健志, 今岡鮎子, 大谷壽一.", 2013.08, 医薬品情報学会 (第16回日本医薬品情報学会総会・学術大会), 免疫抑制剤、βblocker、ステロイドの低用量域における全身性副作用の用量依存性評価.

• 優秀発表賞

  "○青野いづみ, 桑原亜記, 今井奈津美, 剱田侑希, 手塚淑人, 門田佳子, 小林典子, 鈴木小夜, 大谷壽一, 佐伯晴子, 木津純子.", 2013.03, 日本薬学会第133年会, 学生主体で構築した新たな服薬指導事前実習の評価.

display all >>

Courses Taught 【 Display / hide 】

Courses Taught 【 Display / hide 】

• STUDY OF MAJOR FIELD: (CLINICAL PHARMACY)

  2025

• SEMINAR:(CLINICAL PHARMACY)

  2025

• RESEARCH FOR BACHELOR'S THESIS 1

  2025

• PRIOR LEARNING FOR CLINICAL PRACTICE 2

  2025

• PHARMACOLOGY FOR NURSING AND HEALTH CARE

  2025

display all >>

Courses Previously Taught 【 Display / hide 】

Courses Previously Taught 【 Display / hide 】

• 薬学への招待

  Keio University

  2015.04

  -

  2016.03

  , 

  Spring Semester, Lecture

• C16(2)剤形をつくる

  Keio University

  2015.04

  -

  2016.03

  , 

  Autumn Semester, Lecture

• C15(3)テーラーメイド薬物治療を目指して

  Keio University

  2015.04

  -

  2016.03

  , 

  Spring Semester, Lecture, Within own ｆaculty

• 臨床物理薬剤・製剤学

  Keio University

  2015.04

  -

  2016.03

  , 

  Spring Semester, Lecture

• 老年薬学と在宅医療

  Keio University

  2015.04

  -

  2016.03

  , 

  Autumn Semester, Lecture

display all >>

Educational Activities and Special Notes 【 Display / hide 】

Educational Activities and Special Notes 【 Display / hide 】

• 第3回アジア薬科大学連合 Deans Forum "Regional Harmonization of Pharmacy Education in Asia" (組織委員・座長・ポスター発表)

  2014.06

  , Lecture at Education Method and Practice

Social Activities 【 Display / hide 】

Social Activities 【 Display / hide 】

• JGSDF (Japanese Army) Reserve

  2011.11

  -

  Present

  　View Summary

  Reserve Lieutenant Colonel (Pharmacy Officer)

Media Coverage 【 Display / hide 】

Media Coverage 【 Display / hide 】

• 薬をジュースで飲んだらダメ？

  朝日新聞 (土曜版（ｂｅ）５面) , 2024.11

  　View Summary

  取材協力

• スポットライト

  株式会社ファーマシィ, TURNUP (第59号 P4〜P10) , 2022.10

• 薬機法違反、出品者は認識を　ネットオークションで健康食品に効能効果表示

  産経新聞 (朝刊) , 2017.07

• 「がんが防げる」「アトピーが緩和される」　ヤフオクで薬機法違反の表示が溢れていた

  J-Cast ニュース > ヘルス&ビューティー, 2017.04

• ヤフオクに多数 効能効果標ぼう食品　慶大薬学部・大谷教授らが調査

  健康産業流通新聞, 2017.04

display all >>

Memberships in Academic Societies 【 Display / hide 】

Memberships in Academic Societies 【 Display / hide 】

• The Pharmaceutical Society of Japan, 

  1990

  -

  Present

• Japanese Society of Pharmaceutical Health Care and Sciences, 

  1997

  -

  Present

• Japanese Society of Drug Informatics (JASDI)

  　

• 日本薬理学会

  　

Committee Experiences 【 Display / hide 】

Committee Experiences 【 Display / hide 】

• 2023.10

  -

  2029.09

  Associate Member, Science Council of Japan

• 2019.02

  -

  Present

  臨時委員, 薬事・食品衛生審議会

  　View Remarks

  医薬品第一部会

• 2009.05

  -

  Present

  Expert Committee Member, Pharmaceuticals and Medical Devices Agency

• 2010.04

  -

  Present

  学術評議員, 日本薬理学会

• 2009.04

  -

  Present

  Examination Committee Member, MR Education & Accreditation Center of Japan

display all >>